Roy S. Herbst, MD, PhD, on Osimertinib for NSCLC: Clinical Implications of a Potentially Practice-Changing Finding

Posted: Friday, May 29, 2020

Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses the positive findings in the ADAURA study on osimertinib in stage IB–IIIA EGFR mutation–positive non–small cell lung cancer and the impact it will have on patients by preventing metastases and giving them an oral therapy option.